60P - Expression of PD-L1 is associated with poor prognosis in breast cancer: A meta-analysis

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Translational Research
Presenter minghui Zhang
Citation Annals of Oncology (2016) 27 (suppl_9): ix9-ix18. 10.1093/annonc/mdw574
Authors M. Zhang
  • Medical Oncology, 3rd Affiliated Hospital of Harbin Medical University, 150081 - Harbin/CN

Abstract

Background

The association of programmed cell death 1 ligand (PD-L1) with the prognosis of various cancers has been a research topic of considerable interest. However, the prognostic value of PD-L1 remains controversial in breast cancer patients.

Methods

A systematic search of the PubMed, EMBASE, and Cochrane Library databases was performed to identify the correlation between PD-L1 expression and clinicopathological features and overall survival (OS).

Results

A total of 5 studies containing 2,546 cases were included. The combined hazard risk (HR) and its 95% confidence interval (CI) for OS was 1.76 (95% CI 1.09–2.82; P = 0.02) for patients with tumors exhibiting PD-L1 overexpression. Subgroup analysis revealed that higher PD-L1 expression was associated with poor prognosis in Asian populations (HR 1.53, 95% CI 1.17–2.01; P = 0.002) but not in non-Asian populations (HR 1.69, 95% CI 0.48–5.98; P = 0.42). The pooled odds ratios (ORs) indicated that PD-L1 expression was associated with positive lymph nodal metastasis, higher histological grade, estrogen receptor (ER)-negative, and triple negative breast cancer (TNBC).

Conclusions

Our findings indicate that PD-L1 expression is a promising biomarker for the prognosis of breast cancer, and these insights might be helpful in selecting the appropriate immunotherapy for breast cancer.

Clinical trial indentification

Legal entity responsible for the study

N/A

Funding

Natural Science Foundation of Heilongjiang Province [No.H201335]

Disclosure

All authors have declared no conflicts of interest.